Recognition of Extraordinary Gain (Gain on Sale of Investment Securities)
Kidswell Bio Corporation (filing company)
1 listed security held by the company (name not disclosed)
To strengthen the financial position and improve asset efficiency
Expected to record a ¥221.717 million gain on sale of investment securities as an extraordinary gain
The beginning of the text states the second-quarter consolidated accounting period of the fiscal year ended March 2026, while the outlook refers to the second quarter of the fiscal year ending March 2027
If it becomes necessary to review the consolidated earnings forecast for the current fiscal year, including other factors, the company will promptly provide an update
The gain on sale of investment securities will be recorded as an extraordinary gain in the second quarter of the fiscal year ending March 2027. If it becomes necessary to review the earnings forecast, the company will promptly provide an update
The Company will promptly disclose any revision if it becomes necessary to revise its earnings forecast.
| Item | Details |
|---|---|
| Event name | Recognition of Extraordinary Gain (Gain on Sale of Investment Securities) |
| Date of occurrence | 1–18 September 2026 (period during which the investment securities sale occurred) |
| Subject Entity | Kidswell Bio Corporation (filing company) |
| Target Locations / Products | 1 listed security held by the company (name not disclosed) |
| Cause | To strengthen the financial position and improve asset efficiency |
| Amount of Impact on Business Performance | Expected to record a ¥221.717 million gain on sale of investment securities as an extraordinary gain |
| Accounting period in which recognized | The beginning of the text states the second-quarter consolidated accounting period of the fiscal year ended March 2026, while the outlook refers to the second quarter of the fiscal year ending March 2027 |
| Impact on Earnings Forecast | If it becomes necessary to review the consolidated earnings forecast for the current fiscal year, including other factors, the company will promptly provide an update |
| Outlook | The gain on sale of investment securities will be recorded as an extraordinary gain in the second quarter of the fiscal year ending March 2027. If it becomes necessary to review the earnings forecast, the company will promptly provide an update |
| Planned follow-up disclosure | The Company will promptly disclose any revision if it becomes necessary to revise its earnings forecast. |
Items this document does not state (15)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To strengthen the financial position and improve asset efficiency.